
    
      The primary objective of this study is to investigate if donor lymphocytes depleted of TCR-αβ
      T cells and B cells can be infused on Day 28 following allogeneic stem cell transplantation
      without inducing Grade III-IV graft versus host disease, Grade II GVHD requiring systemic
      treatment and or new onset, severe neutropenia requiring growth factor support.

      This study also seeks to characterize the lymphocyte subsets obtained following depletion of
      TCR-αβ T cells and B cells from non-mobilized, leukapheresis products.

      Additionally, this study will attempt to describe occurrence of disease relapse and to
      describe the occurrence of post-transplant re- activation and/or infections with viruses such
      as CMV, and EBV.
    
  